Skip to content
10-Q

Quarterly Report

REGENERX BIOPHARMACEUTICALS, INC.

0001104659-20-125049

← back to feed
Filed
Nov 13, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2020 · Nov 10, 2020 133.44M sh
Cash And Equivalents Q3 2020 · Sep 30, 2020 $138.81K
Cash And Equivalents Q3 2020 · Dec 31, 2019 $639.92K
Current Liabilities Q3 2020 · Sep 30, 2020 $345.02K
Current Liabilities Q3 2020 · Dec 31, 2019 $242.47K
Total Liabilities Q3 2020 · Sep 30, 2020 $3.26M
Total Liabilities Q3 2020 · Dec 31, 2019 $3.05M
Current Assets Q3 2020 · Sep 30, 2020 $197.44K
Current Assets Q3 2020 · Dec 31, 2019 $681.56K
Total Assets Q3 2020 · Sep 30, 2020 $280.36K
Total Assets Q3 2020 · Dec 31, 2019 $711.76K
Shares Diluted Q3 2020 · Sep 30, 2019 131.51M sh
Shares Diluted Q3 2020 · Sep 30, 2019 130.79M sh
Operating Cash Flow Q3 2020 · Sep 30, 2019 −$896.07K
Stockholders Equity Q3 2020 · Sep 30, 2019 −$2.04M
Stockholders Equity Q3 2020 · Jun 30, 2019 −$1.76M
Stockholders Equity Q3 2020 · Mar 31, 2019 −$1.96M
Stockholders Equity Q3 2020 · Dec 31, 2018 −$2.21M
Eps Diluted Q3 2020 · Sep 30, 2019 $0.00
Eps Diluted Q3 2020 · Sep 30, 2019 −$0.01
Eps Basic Q3 2020 · Sep 30, 2019 $0.00
Eps Basic Q3 2020 · Sep 30, 2019 −$0.01
Sga Expense Q3 2020 · Sep 30, 2019 $293.95K
Sga Expense Q3 2020 · Sep 30, 2019 $965.5K
Rd Expense Q3 2020 · Sep 30, 2019 $11.73K
Rd Expense Q3 2020 · Sep 30, 2019 $53.37K
Net Income Q3 2020 · Sep 30, 2019 −$333.91K
Net Income Q3 2020 · Sep 30, 2019 −$1.05M
Net Income Q3 2020 · Jun 30, 2019 −$388.45K
Net Income Q3 2020 · Mar 31, 2019 −$332.45K
Operating Income Q3 2020 · Sep 30, 2019 −$286.5K
Operating Income Q3 2020 · Sep 30, 2019 −$961.3K
Revenue Q3 2020 · Sep 30, 2019 $19.19K
Revenue Q3 2020 · Sep 30, 2019 $57.57K